EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

USPTO’s Lax Policy Leads to Humira Formulation Thicket

Bernard Chao

Journal of Law, Medicine & Ethics · 2024

DOI: 10.1017/jme.2024.132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, 2024. Verfasst von Bernard Chao. Beteiligte Einrichtung: UNIVERSITY OF DENVER, DENVER, COLORADO, USA. Hauptthemen laut MEDLINE: Patents as Topic, Biosimilar Pharmaceuticals. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patents as TopicBiosimilar PharmaceuticalsUnited StatesHumansDrug Industry

Stichwörter der Autor:innen

BiologicsComparative LawFormulationsPatentsWritten Description

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • UNIVERSITY OF DENVER, DENVER, COLORADO, USA.

Zitieren

APA

Chao, B. (2024). USPTO’s Lax Policy Leads to Humira Formulation Thicket. Journal of Law, Medicine & Ethics. https://doi.org/10.1017/jme.2024.132

Vancouver

Chao B. USPTO’s Lax Policy Leads to Humira Formulation Thicket. Journal of Law, Medicine & Ethics. 2024. doi:10.1017/jme.2024.132

BibTeX
@article{Chao2024,
  author = {Chao, Bernard},
  title = {USPTO’s Lax Policy Leads to Humira Formulation Thicket},
  journal = {Journal of Law, Medicine & Ethics},
  year = {2024},
  doi = {10.1017/jme.2024.132}
}
Kostenlos starten →